BR0313546A - Uso de acetato de anacortave para a proteção de acuidade visual em pacientes com degeneração macular relacionada com a idade - Google Patents

Uso de acetato de anacortave para a proteção de acuidade visual em pacientes com degeneração macular relacionada com a idade

Info

Publication number
BR0313546A
BR0313546A BR0313546-2A BR0313546A BR0313546A BR 0313546 A BR0313546 A BR 0313546A BR 0313546 A BR0313546 A BR 0313546A BR 0313546 A BR0313546 A BR 0313546A
Authority
BR
Brazil
Prior art keywords
patients
age
macular degeneration
visual acuity
related macular
Prior art date
Application number
BR0313546-2A
Other languages
English (en)
Inventor
Janice A Jerdan
Patricia Zilliox
Stella M Robertson
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of BR0313546A publication Critical patent/BR0313546A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)

Abstract

"USO DE ACETATO DE ANACORTAVE PARA A PROTEçãO DE ACUIDADE VISUAL EM PACIENTES COM DEGENERAçãO MACULAR RELACIONADA COM A IDADE". A presente invenção refere-se ao uso do acetato de anacortave ou do álcool do mesmo para a proteção da acuidade visual em pacientes com degeneração macular devida a idade.
BR0313546-2A 2002-08-05 2003-06-26 Uso de acetato de anacortave para a proteção de acuidade visual em pacientes com degeneração macular relacionada com a idade BR0313546A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40122002P 2002-08-05 2002-08-05
PCT/US2003/020154 WO2004012742A1 (en) 2002-08-05 2003-06-26 Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration

Publications (1)

Publication Number Publication Date
BR0313546A true BR0313546A (pt) 2005-07-12

Family

ID=31495940

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0313546-2A BR0313546A (pt) 2002-08-05 2003-06-26 Uso de acetato de anacortave para a proteção de acuidade visual em pacientes com degeneração macular relacionada com a idade

Country Status (17)

Country Link
US (2) US20060166956A1 (pt)
EP (1) EP1539182A4 (pt)
JP (1) JP2005535691A (pt)
KR (1) KR20050026510A (pt)
CN (1) CN1674913A (pt)
AR (1) AR040599A1 (pt)
AU (1) AU2003281817A1 (pt)
BR (1) BR0313546A (pt)
CA (1) CA2494211A1 (pt)
DE (1) DE03742226T1 (pt)
ES (1) ES2244361T1 (pt)
MX (1) MXPA05000773A (pt)
PL (1) PL375024A1 (pt)
RU (1) RU2322239C2 (pt)
TW (1) TW200410699A (pt)
WO (1) WO2004012742A1 (pt)
ZA (1) ZA200500731B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL375024A1 (en) * 2002-08-05 2005-11-14 Alcon, Inc. Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration
CA2516790A1 (en) * 2003-02-20 2004-09-02 Alcon, Inc. Formulations of glucocorticoids to treat pathologic ocular angiogenesis
WO2004112796A1 (en) * 2003-06-20 2004-12-29 Alcon, Inc. Treatment of amd with combination of ingredients
CN1852700A (zh) * 2003-09-23 2006-10-25 爱尔康公司 曲安奈德和醋酸阿奈可他注射用制剂
US7257366B2 (en) * 2003-11-26 2007-08-14 Osmosis Llc System and method for teaching a new language
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US7261529B2 (en) * 2005-09-07 2007-08-28 Southwest Research Institute Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US9693967B2 (en) * 2005-09-07 2017-07-04 Southwest Research Institute Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates
US7758778B2 (en) * 2005-09-07 2010-07-20 Southwest Research Institute Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents
WO2007047626A1 (en) * 2005-10-14 2007-04-26 Alcon, Inc. Combination treatment with anecortave acetate and bevacizumab or ranibizumab for pathologic ocular angiogenesis
CN101563051A (zh) * 2006-12-18 2009-10-21 爱尔康研究有限公司 眼用药物递送的装置与方法
CN101759741B (zh) * 2008-11-06 2013-01-09 天津金耀集团有限公司 一种化合物及其在制备治疗血管新生的药物中的应用
CN101923856B (zh) 2009-06-12 2012-06-06 华为技术有限公司 语音识别训练处理、控制方法及装置
CA2865132A1 (en) * 2012-02-22 2013-08-29 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
RU2489146C1 (ru) * 2012-07-11 2013-08-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт глазных болезней" Российской академии медицинских наук (ФГБУ "НИИГБ" РАМН) Способ лечения "сухой" формы возрастной макулярной дегенерации

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4876250A (en) * 1988-10-31 1989-10-24 Alcon Laboratories, Inc. Methods for controlling ocular hypertension with angiostatic steroids
US5371078A (en) * 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5679666A (en) * 1991-11-22 1997-10-21 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
AU768400B2 (en) * 1999-10-21 2003-12-11 Alcon Inc. Drug delivery device
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
PL375024A1 (en) * 2002-08-05 2005-11-14 Alcon, Inc. Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration
WO2007047626A1 (en) * 2005-10-14 2007-04-26 Alcon, Inc. Combination treatment with anecortave acetate and bevacizumab or ranibizumab for pathologic ocular angiogenesis

Also Published As

Publication number Publication date
CA2494211A1 (en) 2004-02-12
MXPA05000773A (es) 2005-04-19
AR040599A1 (es) 2005-04-13
JP2005535691A (ja) 2005-11-24
WO2004012742A1 (en) 2004-02-12
RU2322239C2 (ru) 2008-04-20
KR20050026510A (ko) 2005-03-15
PL375024A1 (en) 2005-11-14
ZA200500731B (en) 2006-08-30
EP1539182A1 (en) 2005-06-15
CN1674913A (zh) 2005-09-28
US20060166956A1 (en) 2006-07-27
DE03742226T1 (de) 2006-03-09
TW200410699A (en) 2004-07-01
RU2005106234A (ru) 2005-08-10
ES2244361T1 (es) 2005-12-16
AU2003281817A1 (en) 2004-02-23
EP1539182A4 (en) 2010-01-20
US20040127472A1 (en) 2004-07-01

Similar Documents

Publication Publication Date Title
BR0313546A (pt) Uso de acetato de anacortave para a proteção de acuidade visual em pacientes com degeneração macular relacionada com a idade
WO2006035237A3 (en) Methods and compositions relating to alzheimer's disease
BRPI0407897A (pt) derivados de cianopiridina úteis no tratamento de cáncer e outros distúrbios
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
WO2008006535A3 (en) Use of a cationic colloidal preparation for the diagnosis and treatment of ocular diseases
WO2008037380A3 (de) Alkylbenzoat gemische
HK1089376A1 (en) Formulation for use in the prevention and treatment of carbohydrate induced ; diseases and conditions
WO2001090091A8 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
SI1594833T1 (sl) Derivati 1-fenilalkankarboksilne kisline za zdravljenje nevrodegenerativnih bolezni
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
BRPI0414699A (pt) formulações de acetato de anecortave e acetonida de triancinolona para injeção
BRPI0520258A2 (pt) uso de uma composição farmacêutica, método para preparar uma composição farmacêutica, e, uso de uma quantidade eficaz de acetato de eslicarbazepina
AU2002347671A1 (en) Ophthalmic device for administering fluid eye medication to the human eye
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2000021528A8 (en) Use of ophthalmic composition comprising vitamin a and vitamin e
WO2007017146A3 (en) Use of collismycin and derivatives thereof as oxidative stress inhibitors
BRPI0407742A (pt) uso de glicocorticóides para preparação de formulação utilizáveis no tratamento de angiogênese ocular patológica, bem como formulção assim obtida
CA2436511A1 (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
RS44304A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
TW200504051A (en) Novel acridine derivatives and their use as medicaments
UY28047A1 (es) Derivados de 7h-dibenzo(b,g)(1,5)dioxocin-5-ona y su uso
AU2001273801A1 (en) Dehydrobaimuxinol derivatives use as medicaments for treating or preventing regressive diseases of brain

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8AANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.